NCT00002373View on ClinicalTrials.gov

The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

Not specified

Conditions
Cytomegalovirus InfectionsHIV Infections
Interventions
DRUG

Maribavir

Trial Locations (2)

94110

Univ of California/ San Francisco / Dept of Medicine, San Francisco

94115

Dr Jacob Lalezari, San Francisco

Sponsors

Lead Sponsor

Glaxo Wellcome
All Listed Sponsors
lead

Glaxo Wellcome

INDUSTRY

NCT00002373 - The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients | Biotech Hunter | Biotech Hunter